Zhengyu Jiang

发表

CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation

J. Zhao, Q. You, Yu-Ting Liu, 2019, Redox biology.

A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2016, Molecular bioSystems.

Binding thermodynamics and kinetics guided optimization of potent Keap1–Nrf2 peptide inhibitors

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2015 .

Design, synthesis, and initial evaluation of affinity-based small molecular probe for detection of WDR5.

Q. You, Zhengyu Jiang, Dongdong Li, 2018, Bioorganic chemistry.

Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury.

Li Li, Lei Wang, Q. You, 2018, European journal of medicinal chemistry.

Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Inhibition: An Emerging Strategy in Cancer Therapy.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2018, Journal of medicinal chemistry.

Novel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2014 .

Design, Synthesis and Structure-Activity Relationships of Indoline-Based Kelch-like ECH Associated Protein 1-Nuclear Factor (Erythroid-derived 2)-like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.

J. Zhao, Q. You, Tian Liu, 2020, Journal of medicinal chemistry.

Synthesis and evaluation of novel aza-caged Garcinia xanthones.

Q. You, Q. Guo, Zhengyu Jiang, 2012, Organic & biomolecular chemistry.

3-aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-ones as potent Nrf2/ARE inducers in human cancer cells and AOM-DSS treated mice.

M. Zhang, R. Hu, Q. You, 2013, Journal of medicinal chemistry.

Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.

Q. You, Meng-Chen Lu, Tian Liu, 2020, European journal of medicinal chemistry.

Discovery of a Potent Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-induced Hepatotoxicity.

Q. You, Jing Zhao, Meng-Chen Lu, 2019, Journal of medicinal chemistry.

Design , Synthesis , and Initial Evaluation of A ffi nity-Based Small-Molecule Probes for Fluorescent Visualization and Speci fi c Detection of Keap 1

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2016 .

Design, Synthesis, and Initial Evaluation of Affinity-Based Small-Molecule Probes for Fluorescent Visualization and Specific Detection of Keap1.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2016, Journal of medicinal chemistry.

Computer-Aided Design and Synthesis of 1-{4-[(3,4-Dihydroxybenzylidene)amino]phenyl}-5-oxopyrrolidine-3-carboxylic Acid as an Nrf2 Enhancer.

H. Senderowitz, M. B. Major, D. Offen, 2018, ChemPlusChem.

Insight into the Intermolecular Recognition Mechanism between Keap1 and IKKβ Combining Homology Modelling, Protein-Protein Docking, Molecular Dynamics Simulations and Virtual Alanine Mutation

Q. You, Zhengyu Jiang, Haopeng Sun, 2013, PloS one.

Proteolysis-targeting chimeras: a kaleidoscope of targeted protein degradation.

Zhengyu Jiang, Y. Mou, Shuai Wen, 2021, Future medicinal chemistry.

Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.

Q. You, Zhengyu Jiang, Ze-Zhou Yu, 2020, Drug discovery today.

3-(1H-Benzo[d]imidazol-6-yl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (DDO7232), a Novel Potent Nrf2/ARE Inducer, Ameliorates DSS-Induced Murine Colitis and Protects NCM460 Cells against Oxidative Stress via ERK1/2 Phosphorylation

Li Li, Lei Wang, Q. You, 2018, Oxidative medicine and cellular longevity.

Corrigendum to “3-(1H-Benzo[d]imidazol-6-yl)-5-(4-fluorophenyl)-1, 2, 4-oxadiazole (DDO7232), a Novel Potent Nrf2/ARE Inducer, Ameliorates DSS-Induced Murine Colitis and Protects NCM460 Cells against Oxidative Stress via ERK1/2 Phosphorylation”

Li Li, Lei Wang, Q. You, 2018, Oxidative medicine and cellular longevity.

Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2015, Journal of medicinal chemistry.

Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile.

Weikang Yang, Q. You, Zhengyu Jiang, 2020, ACS medicinal chemistry letters.

Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.

Zhengyu Jiang, X. Ye, Weikun Zhang, 2022, European journal of medicinal chemistry.

Q. You, Zhengyu Jiang, Li-li Xu, 2016, Bioorganic & medicinal chemistry.

Polar Recognition Group Study of Keap1-Nrf2 Protein-Protein Interaction Inhibitors.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2016, ACS medicinal chemistry letters.

Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.

Zhengyu Jiang, Y. Mou, Xin Zhang, 2020, European journal of medicinal chemistry.

Novel Dual-Site-Binding Neuraminidase Inhibitor from Virtual Screening by Pharmacophore and Molecular Dynamics Methods

Q. You, Zhengyu Jiang, Haopeng Sun, 2012 .

Discovery of 3,5-Dimethyl-4-Sulfonyl-1H-Pyrrole-Based Myeloid Cell Leukemia 1 Inhibitors with High Affinity, Selectivity, and Oral Bioavailability.

Q. You, Zhengyu Jiang, Peng Zhu, 2021, Journal of medicinal chemistry.

Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome.

Q. You, Weikang Tao, Ren Ren, 2022, Journal of medicinal chemistry.

5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress.

Q. You, Bin Di, Zhengyu Jiang, 2019, Free radical biology & medicine.

Synthesis and bioevaluation of a series of α-pyrone derivatives as potent activators of Nrf2/ARE pathway (part I).

R. Hu, Q. You, Q. Guo, 2013, European journal of medicinal chemistry.

The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update

Meng-Chen Lu, Q. You, Meng-Chen Lu, 2016, Medicinal research reviews.

Regulation of Nrf2 by phosphorylation: consequences for biological function and therapeutic implications.

Q. You, Tian Liu, Zhengyu Jiang, 2021, Free radical biology & medicine.

A hydrogen peroxide responsive prodrug of Keap1-Nrf2 inhibitor for improving oral absorption and selective activation in inflammatory conditions

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2020, Redox biology.

p62 as a therapeutic target for tumor.

Q. You, Tian Liu, Mengmin Tao, 2020, European journal of medicinal chemistry.

Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2016, Journal of medicinal chemistry.

Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification.

Li Li, W. Dai, Lei Wang, 2021, Cell chemical biology.

Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway.

Qidong You, Q. You, Meng-Chen Lu, 2018, European journal of medicinal chemistry.

Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery

Lei Wang, Q. You, Zhengyu Jiang, 2020, Acta pharmaceutica Sinica. B.

A JAK tyrosine kinase and pseudokinase Co-inhibition strategy combines enhanced potency and on-demand activation.

Q. You, Zhengyu Jiang, Qi-chao Bao, 2023, European journal of medicinal chemistry.

Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2020, Journal of medicinal chemistry.

Discovery and Design of Tricyclic Scaffolds as Protein Kinase CK2 (CK2) Inhibitors through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification

Fang Liu, Xiaoli Xu, Xiaowen Wu, 2013, J. Chem. Inf. Model..

Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2016, Mini reviews in medicinal chemistry.

Optimization and bioevaluation of Cdc37-derived peptides: An insight into Hsp90-Cdc37 protein-protein interaction modulators.

Li Li, Lei Wang, Q. You, 2017, Bioorganic & medicinal chemistry.

Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.

Q. You, Zhengyu Jiang, Xue Li, 2021, European journal of medicinal chemistry.

Synthesis and evaluation of N-(benzofuran-5-yl)aromaticsulfonamide derivatives as novel HIF-1 inhibitors that possess anti-angiogenic potential.

Q. You, Zhengyu Jiang, Yali Li, 2017, Bioorganic & medicinal chemistry.

Novel IKKβ inhibitors discovery based on the co-crystal structure by using binding-conformation-based and ligand-based method.

Q. You, Zhengyu Jiang, Haopeng Sun, 2013, European journal of medicinal chemistry.

Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2015, Journal of medicinal chemistry.

Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer

Jian Zhang, Li Li, Lei Wang, 2019, Science Advances.

Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia.

Q. You, Zhengyu Jiang, Dongdong Li, 2021, Journal of medicinal chemistry.

Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.

Li Li, Xiao-Li Xu, Li Li, 2017, European journal of medicinal chemistry.

Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2014, Journal of medicinal chemistry.

Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.

Q. You, Meng-Chen Lu, Tian Liu, 2018, European journal of medicinal chemistry.

Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.

Q. You, Zhengyu Jiang, Dongdong Li, 2019, European journal of medicinal chemistry.

An affinity prediction approach for the ligand of E3 ligase Cbl-b and an insight into substrate binding pattern.

Q. You, Zhengyu Jiang, Lvbin Hu, 2021, Bioorganic & medicinal chemistry.

Investigation of the intermolecular recognition mechanism between the E3 ubiquitin ligase Keap1 and substrate based on multiple substrates analysis

Yang Pan, Zhengyu Jiang, Li-Li Xu, 2014, Journal of Computer-Aided Molecular Design.

Recent applications of CBT-Cys click reaction in biological systems.

Q. You, Zhengyu Jiang, Xian Zhang, 2022, Bioorganic & medicinal chemistry.

Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present)

Q. You, Zhengyu Jiang, Haishan Zhou, 2020, Expert opinion on therapeutic patents.

Discovery and Development of Keap1-Nrf2 Protein-Protein Interaction Inhibitors

Q. You, Zhengyu Jiang, 2018 .

Discovery and identification of Cdc37-derived peptides targeting the Hsp90–Cdc37 protein–protein interaction

Lei Wang, Q. You, Zhengyu Jiang, 2015 .

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope

Zhengyu Jiang, Xiaoli Xu, Qi-dong You, 2022, Acta pharmaceutica Sinica. B.

High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.

Q. You, Zhengyu Jiang, Yi-Yue Xie, 2016, European journal of medicinal chemistry.

An updated patent review of Nrf2 activators (2020-present)

Zhengyu Jiang, Qidong You, Ziquan Zhao, 2023, Expert opinion on therapeutic patents.

Development of Orally Bioavailable Amidobenzimidazole Analogues Targeting Stimulator of Interferon Gene (STING) Receptor.

Q. You, Zhengyu Jiang, Xiaoli Xu, 2023, Journal of medicinal chemistry.

Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.

Weitao Fu, Lingfeng Chen, Zhengyu Jiang, 2023, European journal of medicinal chemistry.

ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer.

Zhengyu Jiang, Jing-Long Zhao, Jianai Ji, 2023, Journal of medicinal chemistry.

Targeting m6A binding protein YTHDFs for cancer therapy.

W. Kang, Zhengyu Jiang, Qidong You, 2023, Bioorganic & medicinal chemistry.

Discovery of 1H-Imidazo[4,5-b]pyridine Derivatives as Potent and Selective BET Inhibitors for the Management of Neuropathic Pain.

Wenjing Kang, B. Xiong, D. Cao, 2023, Journal of medicinal chemistry.

Development of Novel Nrf2/ARE Inducers Bearing Pyrazino[2,1-a]isoquinolin Scaffold with Potent In Vitro Efficacy and Enhanced Physicochemical Properties

Q. You, Tian Liu, Zhengyu Jiang, 2017, Molecules.

Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.

Zhengyu Jiang, Qidong You, Ziquan Zhao, 2023, Journal of medicinal chemistry.

Recent advances in the structure-based and ligand-based design of IKKβ inhibitors as anti-inflammation and anti-cancer agents.

Q. You, Zhengyu Jiang, Haopeng Sun, 2014, Current medicinal chemistry.

Novel Hydrogen Sulfide Hybrid Derivatives of Keap1-Nrf2 Protein–Protein Interaction Inhibitor Alleviate Inflammation and Oxidative Stress in Acute Experimental Colitis

Zhengyu Jiang, Xiaoke Guo, Xian Zhang, 2023, Antioxidants.

Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation.

Zhengyu Jiang, Xuanyu Wang, Qidong You, 2023, Journal of the American Chemical Society.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2016, Journal of medicinal chemistry.

Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study.

Q. You, Meng-Chen Lu, Zhengyu Jiang, 2015, Journal of Medicinal Chemistry.

Q. You, Zhengyu Jiang, Li-li Xu, 2016, Bioorganic & medicinal chemistry.

Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis.

Zhengyu Jiang, Qi-chao Bao, R. Xu, 2023, European journal of medicinal chemistry.

Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives.

Zhengyu Jiang, Qidong You, Qiong Zhang, 2024, European journal of medicinal chemistry.

Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML.

Zhengyu Jiang, Xiaoke Guo, Qidong You, 2023, Journal of medicinal chemistry.

Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8.

Zhengyu Jiang, Qidong You, Tingting Wu, 2024, European journal of medicinal chemistry.

Bivalent inhibitors of the BTB E3 ligase KEAP1 enable instant NRF2 activation to suppress acute inflammatory response.

Meng-Chen Lu, Zhengyu Jiang, Jianai Ji, 2023, Cell chemical biology.

Computer-Aided Design and Synthesis of 1-{4-[(3,4-Dihydroxybenzylidene)amino]phenyl}-5-oxopyrrolidine-3-carboxylic Acid as an Nrf2 Enhancer.

H. Senderowitz, D. Offen, Zhengyu Jiang, 2018, ChemPlusChem.

Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.

Q. You, Zhengyu Jiang, Dongdong Li, 2021, European journal of medicinal chemistry.